Search Within

Andrew D Zelenetz

  1. "Epidemiology and Biostatistics"
Formats
  1. Meeting Abstract (79)
  2. Journal Article (72)
  3. Research Letter (2)
Groups
  1. Center for Hematologic Malignancies (153)
  2. Department of Medicine (153)
  3. Epidemiology and Biostatistics (153)
  4. Hematologic Malignancies, Division of (153)
  5. Lymphoma (153)
  6. Biostatistics Service (127)

More Groups

People
  1. Paul Hamlin (75)
  2. Craig Moskowitz (74)
  3. Anita Kumar (68)
  4. Ariela Noy (67)
  5. Maria Palomba (64)
  6. David Straus (63)

More People

Years
  1. 2025 (3)
  2. 2024 (5)
  3. 2023 (12)
  4. 2022 (9)
  5. 2021 (15)
  6. 2020 (9)

More Years

Publications
  1. Blood (64)
  2. Journal of Clinical Oncology (17)
  3. Hematological Oncology (11)
  4. Blood Advances (8)
  5. British Journal of Haematology (8)
  6. Haematologica (6)

More Publications

Publishers
  1. American Society of Hematology (72)
  2. American Society of Clinical Oncology (17)
  3. Wiley Blackwell (11)
  4. Nature Publishing Group (9)
  5. John Wiley & Sons (8)
  6. Elsevier Inc. (7)

More Publishers

Results (153)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Real-world outcomes in patients with transformed follicular lymphoma treated with CD19-targeting CAR-T therapy
    Meeting Abstract

    Rivas-Delgado, A.; Luttwak, E.; Drill, E.; Goldstein, I.; Landego, I.; Tomas, A. A.; Parascondola, A.; Saldia, A.; Caron, P.; Dahi, P. B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A multicenter phase 2 trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in patients with treatment-naïve, TP53-mutant mantle cell lymphoma
    Meeting Abstract

    Kumar, A.; Soumerai, J.; Abramson, J. S.; Barnes, J. A.; Caron, P.; Chabowska, M.; Devlin, M.; Dogan, A.; Falchi, L.; Garcia, R. N.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Treatment outcomes of limited stage grade 3A follicular lymphoma
    Meeting Abstract

    Sarkar, R. R.; Lee, J.; Zhang, Z.; Zelenetz, A. D.; Salles, G.; Yahalom, J.; Imber, B. S.
    Blood (2023)

    Fulltext@MSK | Save
  • Predicting toxicities in older adults with non-Hodgkin lymphoma (NHL) receiving systemic chemotherapy: A prospective geriatric assessment (GA) study
    Meeting Abstract

    Torka, P.; Drill, E.; Ganesan, N.; Oliveros, M.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy
    Journal Article

    Johnson, W. T.; Ganesan, N.; Epstein-Peterson, Z. D.; Moskowitz, A. J.; Stuver, R. N.; Maccaro, C. R.; Galasso, N.; Chang, T.; Khan, N.; Aypar, U.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Retrospective characterization of nodal marginal zone lymphoma
    Journal Article

    Stuver, R.; Drill, E.; Qualls, D.; Okwali, M.; Batlevi, C. L.; Caron, P. C.; Dogan, A.; Epstein-Peterson, Z. D.; Falchi, L.; Hamlin, P. A.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Treatment outcomes of limited stage grade 3A follicular lymphoma
    Meeting Abstract

    Sarkar, R. R.; Lee, J.; Zhang, Z.; Zelenetz, A.; Salles, G.; Yahalom, J.; Imber, B.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Long‐term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with CLL/SLL
    Meeting Abstract

    Soumerai, J. D.; Dogan, A.; Seshan, V.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Abramson, J. S.; Hamilton, A. M.; Noy, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Prognostic value of (18)F-FDG PET/CT in diffuse large B-cell lymphoma treated with a risk-adapted immunochemotherapy regimen
    Journal Article

    Michaud, L.; Bantilan, K.; Mauguen, A.; Moskowitz, C. H.; Zelenetz, A. D.; Schöder, H.
    Journal of Nuclear Medicine (2023)

    Fulltext@MSK | Save
  • Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: An open label phase II study
    Research Letter

    Qualls, D.; Noy, A.; Straus, D.; Matasar, M.; Moskowitz, C.; Seshan, V.; Dogan, A.; Salles, G.; Younes, A.; Zelenetz, A. D.; more...
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save